Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

28 avr. 2021 07h30 HE | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 creamAdditional submissions slated for France, Germany, Greece, and Italy over the next several days and...
21 déc. 2020 10h28 HE | Source: Research and Markets

Global Medical Cannabis Market Insights, Analysis and Forecasts Report 2020-2025 Featuring TEVA, Cannabis Science, Gb Sciences, Akorn, Cronos Group Among Others

Dublin, Dec. 21, 2020 (GLOBE NEWSWIRE) -- The "Medical Cannabis Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Product Type" report has been added...
20 nov. 2019 07h30 HE | Source: MCTC Holdings Inc. (d/b/a Cannabis Global)

MCTC Expands R&D Program to Include Producing Polymeric Nanoparticles of Valuable, Hard-to-Obtain Cannabinoids

LOS ANGELES, Nov. 20, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – MCTC Holdings Inc. (OTC: MCTC) today announces an expanded R&D program designed to produce polymeric nanoparticles of cannabinol...
25 févr. 2019 07h28 HE | Source: Cannabis Science, Inc.

Cannabis Science Set to Integrate Its Sponsored Research In Nigeria to Include Its U.S. Patent Number 9,763,991 for Compositions of Cannabinol (CBN) for Treatment of Various Neurological Conditions

IRVINE, CA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Pre-Clinical Work and Animal Studies Underway, and Protocols for Clinical Studies Under Development via NEWMEDIAWIRE -- Cannabis Science, Inc....
29 oct. 2018 09h01 HE | Source: Cannabis Science, Inc.

Cannabis Science Confirms Receipt of Issued US Patent Number 9,763,991 For Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, Sleep Deprivation (Insomnia), Anxiety Disorders (ADHD), and (PTSD)

IRVINE, CA, Oct. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to...

Page précédente